BackPainReform Overview
PainReform Ltd

PainReform Discounted Cash Flow

Is PRFX undervalued? Intrinsic value estimate stands at $6.4.

Get informed when a big investor buys or sells

+ Follow

Fair Value

$6.42

Current Fair Value

$6.42
541.6% Upside

Undervalued by 541.6% based on the discounted cash flow analysis.

Average Upside/Downside (Comparison Companies)

Loading

Fair Value vs. Stock Price History

Loading

Upside/Downside History

Loading

Upside/Downside Comparison

Loading

PainReform (PRFX) FAQ

As of the most recent data, PRFX shows a DCF fair value of $6.4. Scroll down for historical charts and peer comparison views.

PainReform's DCF reading of $6.4 (541.6% undervalued) is a model output, not a certainty. Small changes in long-term growth or the discount rate can move fair value a lot. Treat the number as a structured starting point, then verify whether PainReform's recent cash-flow history supports the assumptions.

Besides this discounted cash flow page, Stockcircle has PainReform's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect DCF fair value (currently $6.4) with ownership activity and broader fundamentals.

PainReform's DCF fair value is $6.4; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.